Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Domestic market and developing countries will need doses of Indian vaccines
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Anti-malaria API facility will be operational in 15-18 months
Filing for WHO Emergency Use Authorisation this month
India business contributes to a stellar performance
Robust demand for the product across the Middle East, Africa and Latin America
Drug formulations and biologics make impressive gains
Subscribe To Our Newsletter & Stay Updated
